Prostate Cancer Clinical Trials in Texas

Showing 161-180 of 213 trials

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

NCT03081481

The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.

Prostate Cancer

Sophiris Bio Corp38 participantsStarted Jun 2017

Ocala, Florida, United States • Baltimore, Maryland, United States • New York, New York, United States +5 more locations

COMPLETEDPhase 113 miles

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

NCT00379561

This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have evidence of recurrent local prostate cancer without metastases.

Prostate Cancer

Sophiris Bio Corp24 participantsStarted Mar 2006

Temple, Texas, United States

COMPLETEDPhase 313 miles

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation therapy.

CancerCataractLow Bone Mineral Density+3 more

Amgen769 participantsStarted Nov 2009

Anaheim, California, United States • Laguna Hills, California, United States • Murrieta, California, United States +169 more locations

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Prostate Cancer Trials in Other Cities

Multi-Institutional Registry for Prostate Cancer Radiosurgery

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Vidaza to Restore Hormone Thx Prostate

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Other Conditions in Texas